- Conditions
- Peripheral Nerve Transections, Acute or Planned in Upper Extremity and Facial Nerves
- Interventions
- NTX-001
- Combination Product
- Lead sponsor
- Neuraptive Therapeutics Inc.
- Industry
- Eligibility
- 12 Years to 80 Years
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1993–2016
of 6,882
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infusion Reactions
- Interventions
- unlicensed CBU
- Biological
- Lead sponsor
- New York Blood Center
- Other
- Eligibility
- Not listed
- Enrollment
- 9,999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 59
- States / cities
- Bakersfield, California • Burbank, California • Fullerton, California + 54 more
- Conditions
- Epilepsy
- Interventions
- Lacosamide
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 108
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
- Conditions
- Arrhythmia, Tachycardia, Atrial Fibrillation, Ventricular Fibrillation
- Interventions
- Remote Management, In-Office Care
- Other
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,009 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 127
- States / cities
- Mobile, Alabama • Mesa, Arizona • Scottsdale, Arizona + 124 more
- Conditions
- Hypocalcemia
- Interventions
- paricalcitol injection (Zemplar), Effects on calcium regulation, Administration of elemental Ca during hypocalcemic ICU pts.
- Drug · Behavioral
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 9
- States / cities
- Merced, California • Denver, Colorado • Hudson, Florida + 6 more
- Conditions
- Atrial Fibrillation
- Interventions
- Pulsed Field Ablation by VARIPULSE Catheter with TRUPULSE Generator
- Device
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more
- Conditions
- Oral Mucositis
- Interventions
- MuGard, Control Rinse
- Device
- Lead sponsor
- Access Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 18
- States / cities
- Mesa, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 14 more
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 50
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more
- Conditions
- Type 2 Diabetes
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Masitinib, Imatinib
- Drug
- Lead sponsor
- AB Science
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more
- Conditions
- Hepatic Impairment, Healthy
- Interventions
- Bulevirtide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more
- Conditions
- Obesity, Overweight
- Interventions
- Maridebart cafraglutide, Autoinjector
- Drug · Device
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- San Diego, California • Miami, Florida • Orlando, Florida + 17 more
- Conditions
- Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
- Interventions
- BL-M07D1
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more
- Conditions
- Sarcoma
- Interventions
- semaxanib, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 163 more
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- Modafinil
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more
- Conditions
- Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 201
- States / cities
- Phoenix, Arizona • Burbank, California • Concord, California + 138 more
- Conditions
- Fibromyalgia
- Interventions
- placebo, Xyrem®
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 71
- States / cities
- Auburn, Alabama • Birmingham, Alabama • Montgomery, Alabama + 61 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo
- Drug · Other
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
- Conditions
- Melanoma
- Interventions
- ipilimumab (MDX-010, BMS-734016), Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Laverne, California • San Diego, California + 21 more
- Conditions
- Anaemia
- Interventions
- Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 3,872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 161
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
- Conditions
- Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
- Interventions
- ORX750, Placebo
- Drug
- Lead sponsor
- Centessa Pharmaceuticals (UK) Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Auburn, Alabama • Chandler, Arizona • Scottsdale, Arizona + 24 more
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- Zibotentan/Dapagliflozin, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 1,835 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 64
- States / cities
- Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more